Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2018 ASCO Annual Meeting!


Session: Breast Cancer—Local/Regional/Adjuvant

Type: Poster Session

Time: Saturday June 2, 8:00 AM to 11:30 AM

Location: Hall A

Balancing the risks versus benefits of trastuzumab: A call to action for oncologists, cardiologists, and cardio-oncologists.

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
554

Poster Board Number:
Poster Session (Board #46)

Citation:
J Clin Oncol 36, 2018 (suppl; abstr 554)

Author(s): Moira Katherine Rushton, Isac Lima, Christopher Johnson, Meltem Tuna, Steven Hawken, Susan Faye Dent; University of Ottawa - Post Graduate Medical Education, Ottawa, ON, Canada; The Institute for Clinical Evaluative Sciences, uOttawa, Ottawa, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

Abstract Disclosures

Abstract:

Background: One year of adjuvant trastuzumab (T) is standard for early stage (I-III) HER2 + breast cancer (BC) patients (pts). Cardiac imaging is recommended every 3 months during treatment to monitor for cardiotoxicity (CTx) without evidence this practice improves pt care. Up to 30% of pts will experience transient, asymptomatic, drops in left ventricular ejection fraction (LVEF) on T, which may lead to early termination of T. Our objective was to evaluate the impact of routine CI on disease free (DFS) and overall survival (OS) in early stage HER2+ BC. Methods: Retrospective population-based cohort study of early stage BC pts treated with adjuvant T in Ontario, Canada, 2007–2016. Patient-level data was sourced through the Institute for Clinical Evaluative Sciences, which captures all patients in Ontario. The cohort was divided into three arms; A: 17-18 cycles T, no CTx; B: no CTx, ≤16 cycles T, stopped within 30 days of last cardiac imaging; C: developed CTx. CTx was defined as new diagnosis heart failure (HF), cardiomyopathy (CM) or pulmonary edema within 90 days of last cycle of T. Primary outcome: DFS; secondary outcomes: OS, cancer-specific, and cardiovascular mortality. Survival analysis was performed using Cox and subdistribution hazard models. Results: 4820 pts met inclusion criteria; 4018, 442 and 360 in arms A, B, and C respectively. Median cycles of T were 18, 13 and 14 in arm A, B and C. 5-year DFS was significantly worse in arms B (70.3%; 95% CI 63.5-74.7) and C (74.9%; 69.5-79.5) vs. 93.2% (92.3-94.0) arm A; HR for DFS were 2.96 (2.35-3.72) and 2.41 (1.87–3.12) respectively. 5-year OS was significantly worse in arms B (75.4%) and C (80.1%) vs. arm A (95.2%); HR for OS 3.99 (3.10–5.14) and 2.98 (2.24–3.95) respectively. All p-values were < 0.05. Conclusions: BC pts in Ontario who did not complete adjuvant T had significantly worse DFS and OS. A significant population stopped T shortly after cardiac imaging, without developing CTx, likely due to detection of asymptomatic drops in LVEF. These findings support the need to consider strategies to continue cancer therapy in pts with abnormal cardiac imaging, including concurrent optimization of cardiac function and cardiac risk factors.

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...